Skip to main content

Table 4 Troxacitabine and gemcitabine combination studies in the human pancreatic AsPc-1 xenograft tumor model.

From: Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer

Group Dose and Schedule Tumor Volumes mm3 Day 45 % T/Ca Pvalues
Compared with saline control group
Pvalues
Compared with gemcitabine treated group
Control (Saline) 5 mL/kg IV
q3d × 4
804 -   
Troxacitabine 1 mg/kg IV
q3d × 4
324 41% P = 0.0126  
Troxacitabine 5 mg/kg IV
q3d × 4
90 12% P < 0.001  
Gemcitabine 80 mg/kg IP
q3d × 4
631 79% P = 0.31  
Troxacitabine + Gemcitabine 1 mg/kg IV +
80 mg/kg IP
q3d × 4
215 27% P = 0.0021 P = 0.0074
  1. a Tumor measurements were taken twice weekly. Drug efficacy was assessed at Day 45, time at which animals from the control group had to be sacrificed due to tumor burden, as the percentage of T/C, determined by calculating RVT as: T/C% = 100 × (mean RTV of treated group)/(mean RVT of control group).
  2. Female SCID mice were inoculated SC with 5 × 106 AsPc-1 cells (Day 0). Treatment with troxacitabine and/or gemcitabine was started 14 days after tumor cell inoculation, once the mice had developed palpable tumors.